ClinicalTrials.gg
CompletedNCT07938047Updated Nov 16, 2026

The Effect of Social Cognition and Interaction Training on Patients With Schizophrenia

An interventional study of the social cognition and interaction training in SCHIZOPHRENIA, sponsored by Central South University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Central South University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2025, registered Jan 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies in Schizophrenia by Central South University — 10 open to participants now, 10 under way, 1 of them phase 3. Schizophrenia · Central South University.

Enrollment
18th of 28
60 · median 80
Started
2025
with 2 others
No phase
18 of 34
7 open now
Registered
28th of 34
by date

Among the 34 studies in Schizophrenia by Central South University, this one is the 18th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2025, is one of 18 with no phase, and was the 28th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 34 studies in Schizophrenia by Central South University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Schizophrenia by Central South University, or all of them as a file.
02

Study summary

This study aims to investigate the effect of social cognition and interaction training on patients with schizophrenia. In this randomized controlled trial, patients will be randomly assigned to the social cognition and interaction training group or the general rehabilitation group. The treatment will last for 8 weeks, and data will be collected at baseline and after treatment.

Read the detailed description

This study aims to investigate the effect of social cognition and interaction training (SCIT) on patients with schizophrenia.

In this randomized controlled trial, patients will be randomly assigned to the SCIT group or the conventional rehabilitation group. The SCIT group will undergo a closed-group psychological training for a duration of 8 weeks. SCIT comprises of three modules: "Introduction and Emotions," which develops emotion recognition skills, particularly for suspiciousness; "Figuring Out Situations," which addresses biases like jumping to conclusions, generating alternative interpretations of social situations, increasing flexibility in attributional style, and teaches strategies for making informed social judgments; and "Checking It Out," which consolidates skills for real-life application. The control group will receive general rehabilitation training, such as disease knowledge dissemination. Both groups of patients will receive rehabilitation training therapy (SCIT or disease knowledge dissemination) twice a week, and the treatment will last for 8 weeks. The data will be collected at baseline and after treatment.

03

Conditions studied

  • SCHIZOPHRENIA

Browse trials for

Keywords

  • schizophrenia
  • social cognition and interaction training
  • SCIT
  • social cognition
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Clinical diagnosis of schizophrenia according to .
  • 2. Age between 18-60 years old.
  • 3. Stable mental state, no tendency to self harm or harm others.
  • 4. The patient is able to understand and communicate in Mandarin.
  • 5. There has been no change in medication in the past month and the next two months.
  • 6. The patient has not been diagnosed with any mental illness other than schizophrenia.
  • 7. All patients and their guardians are required to voluntarily sign an form.

Exclusion criteria

Exclusion Criteria:

  • 1. According to the diagnostic criteria of , suffering from mental disorders other than schizophrenia
  • 2. Severe physical disorders or organic brain damage
  • 3. Severe impairment of intellectual function or difficulty in speaking or understanding Mandarin
  • 4. Having suicidal or self-harm intentions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    SCIT group

    The SCIT group will undergo a closed-group psychological training for a duration of 8 weeks. Patients in the SCIT group will undergo social cognition and interaction training twice a week, and the treatment will last for 8 weeks.

    Behavioral: the social cognition and interaction training

  • No intervention
    control group

    During the 8-week study period, participants in the control group continue to take part in the ward's usual rehabilitation activities, such as education about schizophrenia and music-listening activities. They do not receive Social Cognition and Interaction Training (SCIT).

Interventions

  • Behavioralthe social cognition and interaction training

    Social cognition and interaction training (SCIT) comprises of three modules: "Introduction and Emotions," which develops emotion recognition skills, particularly for suspiciousness; "Figuring Out Situations," which addresses biases like jumping to conclusions, generating alternative interpretations of social situations, increasing flexibility in attributional style, and teaches strategies for making informed social judgments; and "Checking It Out," which consolidates skills for real-life application.

06

What researchers measure

Primary outcomes

  1. the Scale for Assessment of Negative Symptoms(SANS)

    The SANS measures the severity of negative symptoms in schizophrenia. It contains 24 items, each item is scored from 0 to 5, higher score indicates more severe symptom. The SANS evaluates five dimensions of the negative symptoms, which are apathy, poverty of thought, abulia, social withdrawal and disorders of attention.

    Time frame: Baseline and Week 8

  2. the Positive and Negative Symptom Scale (PANSS)

    The PANSS measures positive symptoms, negative symptoms and general psychopathology. It contains 30 items, each item is scored from 1 to 7, higher score indicates more severe psychopathology in the dimension. Here the investigators use the Chinese version of the PANSS to evaluate the severity of symptoms in schizophrenia in different participant and different treatment phase. The investigators mainly focus on change in the total score of the negative symptoms.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. the Personal and Social Performance Scale (PSP)

    The Personal and Social Performance Scale (PSP) assesses functioning in four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The four domains inform a single overall score ranging from 1 to 100 points. Higher scores indicate better personal and social functioning.

    Time frame: Baseline and Week 8

  2. the social cognition screening questionnaire (SCSQ)

    The total score is calculated by summing the verbal memory, schematic inference, theory of mind, and metacognition subscale scores. The hostile attributional bias subscale is scored separately. The total score ranges from 0 to 40 points, with higher scores indicating better performance on the SCSQ.

    Time frame: Baseline and Week 8

  3. Facial Emotion Test (FET)

    The Facial Emotion Test (FET) assesses facial emotion recognition ability and consists of 20 items, each with four response options. Each correct response is scored 1 point, and each incorrect response is scored 0 points. Item scores are summed to yield a total score ranging from 0 to 20 points. Higher scores indicate better facial emotion recognition ability.

    Time frame: Baseline and Week 8

  4. The Interpersonal Reactivity Index - Chinese version (IRI-C)

    The IRI-C is a 22-item self-report questionnaire covering Perspective Taking, Empathic Concern, Fantasy, and Personal Distress. Each item is rated from 1 to 5. The original ratings for all 22 items are summed to yield a single total score ranging from 22 to 110 points.

    Time frame: Baseline and Week 8

  5. the Mayer-Salovey-Caruso Emotional Intelligence Test - Managing Emotions(MSCEIT-ME)

    The Managing Emotions branch assesses the ability to evaluate strategies for managing emotions in oneself and in interpersonal situations. Participants rate the effectiveness of possible responses to brief scenarios on a five-point scale. Responses from both tasks are scored according to the MSCEIT scoring procedure to produce a single Managing Emotions branch score. Higher scores indicate better performance.

    Time frame: Baseline and Week 8

  6. The Reading the Mind in the Eyes Test (RMET)

    The Reading the Mind in the Eyes Test (RMET) consists of 36 items. Each correct response is scored 1 point, and each incorrect response is scored 0 points. Item scores are summed to yield a single total score ranging from 0 to 36 points. Higher scores indicate better performance.

    Time frame: Baseline and Week 8

  7. The Animations Test

    Participants view animations of two triangles and classify each animation as random movement, goal-directed interaction, or mental interaction (theory of mind). Each correct classification receives 1 point and each incorrect classification receives 0 points. Scores are summed across all three conditions to yield a single total score. Higher scores indicate more correct classifications. The total score ranges from 0 to 12 points.

    Time frame: Baseline and Week 8

  8. Mean Pupil Diameter

    Pupil diameter is recorded using the Tobii Pro Nano during the Free-Viewing Task, the Reading the Mind in the Eyes Test (RMET), and the Animations Test. Mean pupil diameter is calculated from valid samples collected during each task and reported separately for each task in millimeters (mm).

    Time frame: Baseline and Week 8

  9. Saccade Duration

    Saccade duration is measured using eye-tracking data recorded with the Tobii Pro Nano during the Free-Viewing Task, the Reading the Mind in the Eyes Test (RMET), and the Animations Test. Saccade duration is reported separately for each task in milliseconds (ms).

    Time frame: Baseline and Week 8

  10. Fixation Duration

    Fixation duration is measured using eye-tracking data recorded with the Tobii Pro Nano during the Free-Viewing Task, the Reading the Mind in the Eyes Test (RMET), and the Animations Test. Fixation duration is reported separately for each task in milliseconds (ms).

    Time frame: Baseline and Week 8

  11. Total Fixation Count

    Eye movements are recorded using the Tobii Pro Nano during the Free-Viewing Task, the Reading the Mind in the Eyes Test (RMET), and the Animations Test. The total number of fixations detected during each task is reported separately for each task.

    Time frame: Baseline and Week 8

07

Study locations

1 site
  • Mental Health Institute of Second Xiangya Hospital, CSU
    Changsha, Hunan 410000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Mar 2026, 10 months.

Of 756 non-industry interventional studies with no phase under Schizophrenia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 10 months is below that.

Counting every sponsor, half of 769 studies reached it within 32 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Nov 16, 2026
StartActual
May 1, 2025
Primary completionActual
Mar 1, 2026
CompletionActual
Mar 1, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938047
Responsible party
Renrong Wu (Professor, Central South University) — Principal investigator
First posted
Nov 16, 2026
Start date
May 1, 2025
Primary completion
Mar 1, 2026
Completion
Mar 1, 2026
Last update
Nov 16, 2026

Study contacts

RENRONG WU
study chair · Mental Health Institute of Second Xiangya Hospital,CSU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion